Antikoagulation nach Myokardinfarkt

J. Harenberg; R. Malsch; D. L. Heene

doi:10.1055/s-0038-1660354

Hämostaseologie, Table of Contents

Hamostaseologie 1994; 14(03): 120-126
DOI: 10.1055/s-0038-1660354

Übersichtsarbeiten/Review Articles

Schattauer GmbH

Antikoagulation nach Myokardinfarkt

J. Harenberg

¹I. Medizinische Klinik, Klinikum Mannheim, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg

,

R. Malsch

¹I. Medizinische Klinik, Klinikum Mannheim, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg

,

D. L. Heene

¹I. Medizinische Klinik, Klinikum Mannheim, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg

› Author Affiliations

Abstract

Zusammenfassung

Die Antikoagulation nach Myokardinfarkt hat durch die Entwicklung neuer Anti-thrombotika und die Ergebnisse neuer Studien zur niedrig dosierten Azetylsalizylsäure eine breite Differentialtherapie ermöglicht. Heparine, orale Antikoagulanzien und Azetylsalizylsäure haben dadurch ihre differenzierten Indikationen bei den verschiedenen Formen der myokardialen Schädigung nach Myokardinfarkt erhalten. Durch die Entwicklung von Hirudinen und synthetischen Thrombininhibitoren lassen sich in der Zukunft weitere Fortschritte auf diesem Gebiet erwarten.

Schlüsselwörter

Myokardinfarkt - Antikoagulation - Heparin - Azetylsalizylsäure - Hirudin

Full Text

References

LITERATUR
1 Reyers I, De Gaetano G, Donati MB. Prolongation by warfarin of “template” bleeding time in rats; a vitamin K-dependent effect. Proc Soc Exp Biol Med 1986; 181: 275-6.
2 De Boer-Van den Berg MAG, Thijssen HHW, Vermeer C. The in vivo effects of acenocoumarol, phenprocoumon and warfarin on vitamin K-dependent carboxylase in various tissues of the rat. Biochem Biophys Acta 1986; 884: 150-7.
3 Green D, Chung-Him SaoT. Warfarin-induced factor VII deficiency and the bleeding time. Thromb Res 1983; 29: 403-6.
4 Borchgrevink CF, Dae LNW. Side effects of coumarin and indadione derivatives. In: Nebenwirkungen und Blutungen bei Antikoagulanzien und Fibrinolytika. Zucker-schwerdt L, Thies HA. (Hrsg) Stuttgart: Schattauer; 1982
5 Millenson MM, Bauer KA, Kistler JP, Bar-zegar S, Tulin L, Rosenberg RD. Monitoring “mini-intensity” anticoagulation with warfarin: Comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment FI+2 levels. Blood 1992; 79: 2034-8.
6 Shetty HG, Backhouse G, Bentley DP, Routledge PA. Effective reversal of warfarin-induced excessive anticoagulation with low dose vitamin K_x . Thromb Haemost 1992; 67: 13-5.
7 Harenberg J. Klinische Pharmakologie von Heparinen. Hämostaseologie 1992; 12: 23-36.
8 Hirsh J, van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WI. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976; 53: 691-5.
9 Schrader J, Valentin R, Tönnis HJ, Hildebrand I. Stibbe W, Amstrong VW, Kandt M, Kästering H, Quellhorst E. Low molecular weight heparin in hemodialysis and hémofiltration patients. Kidney 1983; 28: 823-9.
10 Harenberg J, Roebruck P, Stehle G, Habscheidt W, Biegholdt M, Heene DL. Heparin study in internal medicine (HESIM) design and preliminary results. Thromb Res 1992; 68: 33-43.
11 Brune K, Lanz R. Mode of action of peripheral analgetics. Drug Res 1984; 34: 1060-4.
12 Levy G. Pharmakokinetics of salicylate in man. Drug Metab Rev 1979; 09: 3-81.
13 Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin like drugs. Nature 1971; 231: 232-4.
14 Mielke CJJR, Kaneshiro MM, Maher IA, Weiner JM, Rapaport SI. The standardized normal Ivy-bleeding time and its prolongation by aspirin. Blood 1969; 34: 204.
15 Appel KF, Vogt A, von Essen R, Tebbe U, Feuerer W, Neuhaus KL. Do we achieve optimal reperfusion in acute myocardial infarction by thrombolysis?. Eur Heart J 1992; 13: 155.
16 ISIS-2 (Second International Study on Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS 2. Lancet 1988; 02: 349-60.
17 Roux S, Christeller S, Ludin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis. A metaanalysis. J Am Coll Cardiol 1992; 19: 671-7.
18 Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66: 1412-7.
19 Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990; 323: 1433-7.
20 Hsia J, Kleiman N, Aguire F, Chaitman BR, Roberts R, Ross AM. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: Relation to coronary artery disease. J Am Coll Cardiol 1992; 20: 31-5.
21 Topol EJ, George BS, Keriakis DJ. et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989; 79: 281-6.
22 Granger C, Kalbfleisch J, Califf R, Woodlief L, Karnash S, Topol EJ. The global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries: (GUSTO) pilot study combines streptokinase and rt-PA. Circulation 1991; 84: 573.
23 Neri GGSerneri, Gensini GF, Carnovali M, Rovelli F, Pirelli S, Fortini A. Effectiveness of low-dose heparin in prevention of myocardial reinfarction. Lancet 1987; 01: 937-42.
24 Turpie AGG, Robinson JG, Doyle DJ, Mul-ji AS, Mishkel GJ, Sealey BJ, Cairns JA, Skingley L, Hirsh J, Gent M. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med 1989; 320: 352-7.
25 Loeliger EA. Oral anticoagulation in patients surviving myocardial infarction. A new approach to old data. Eur J Clin Pharmacol 1984; 26: 137-9.
26 Leizorovicz A, Boissel JP. Oral anticoagulants in patients surviving myocardial infarction. A new approach to old data. Eur J Clin Pharmacol 1983; 24: 333-6.
27 Bjerkelung CJ. The effect of long-term treatment with dicoumaron in myocardial infarction. Acta Med Scand 1957; 158 (Suppl 330) 12-212.
28 Borchgrevink CF. Long-term anticoagulant therapy in angina pectoris and myocardial infarction. Acta Med Scand 1960; 359 (Suppl) 7-52.
29 British Medical Research Council. An assessment of long-term anticoagulant administration after cardial infarction. Br Med J 1964; 02: 837-43.
30 Asperstrom G, Korsan-Bengtsen K. A double-blind study of dicoumaron prophylaxis in coronary heart disease. Acta Med Scand 1964; 176: 563-75.
31 Rozenberg MC, Kronenberg H, Firkin BG. “Thrombotest” and prothrombin time: a controlled clinical trial. Ann Med 1965; 14: 3-12.
32 Loeliger EA, Hensen A, Kroes F. A doubleblind trial of long-term anticoagulant treatment after myocardial infarction. Acta Med Scand 1967; 182: 549-66.
33 Meuwissen OJAT, Vervoorn AC, Cohen O. Double-blind trial of long-term anticoagulant treatment after myocardial infarction. Acta Med Scand 1969; 186: 361-8.
34 Sorensen OH, Friis T, Jorgensen AW. Anticoagulant treatment of acute coronary thrombosis. Acta Med Scand 1969; 185: 65-72.
35 Sixty Plus Reinfarction Study Research Group. Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1982; 01: 64-8.
36 MacMillan RL, Brown KGW, Watt DL. Long-term anticoagulant therapy after myocardial infarction. Can Med Assoc J 1969; 83: 567-70.
37 Harvald B, Hilden T, Lund E. Long-term anticoagulant therapy after myocardial infarction. Lancet 1962; 02: 626-30.
38 Clausen J, Andersen PE, Andresen P. Land-tids-antikoagulansbehandling efter akut hjertinfarkt. Ugeskr Laeger 1961; 123: 973-83.
39 Conrad LL, Kryiacopoulos JD, Wiggins CW. Prevention of recurrences of myocardial infarction. Arch Int Med 1964; 114: 348-58.
40 Lovell RHH, Denborough MA, Nestel PJ. et al. À controlled trial of long-term treatment with anticoagulant after myocardial infarction in 412 male patients. Med J Austral 1967; 02: 97-104.
41 Ebert RV, Borden CW, Hipp HR. Longterm anticoagulant therapy after myocardial infarction. J Am Med Assoc 1969; 207: 2263-7.
42 Seaman AJ, Griswold HE, Beaume RB. Long-term anticoagulant prophylaxis after myocardial infarction. N Engl J Med 1969; 281: 115-9.
43 Ritland S, Lygren T. Comparison of efficacy of 3 and 12 months’ anticoagulant therapy after myocardial infarction. Lancet 1969; 01: 122-4.
44 Breddin K, Loew D, Lechner K. Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Haemostasis 1980; 09: 325-44.
45 EPSIM Research Group. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982; 307: 701-8.
46 Loeliger EA, Hensen A, Kroes F, van Dijk LM, Fekkes N, de Jonge H, Hemker HC. A double-blind trial of long-term anticoagulant treatment after myocardial infarction. Acta Med Scand 1967; 182: 549-66.
47 Report of the Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980; II: 989-94.
48 Smith P, Arnesen H, Abdelnoor M. Effects of long-term anticoagulant therapy in subgroups after acute myocardial infarction. Arch Intern Med 1992; 152: 993-7.
49 Keyes JW, Drake EH, Smith FJ. Survival rates after acute myocardial infarction with long-term anticoagulant therapy. Circulation 1956; 14: 254-9.
50 Harenberg J, Haas S, Zimmermann R. Measurement of fibrinopeptide A in patients treated with phenprocoumon. Thromb Haemost 1981; 45: 282-4.
51 Kornberg A, Francis CW, Pellegrine VD, Gabriel KR, Marder VJ. Comparison of native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant prophylaxis. Circulation 1993; 88: 454-60.
52 Harenberg J, Haas R, Zimmermann R. Plasma hypercoagulability after termination of oral anticoagulants. Thromb Res 1983; 29: 627-32.
53 Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
54 Schreiber TL, Miller DH, Silvasi D, McNulty A, Zola BE. Superiority of warfarin over aspirin long-term after thrombolytic therapy for acute myocardial infarction. Am Heart J 1990; 119: 1238-44.
55 Kouvaras G, Chronopoulos G, Soufras G, Sofronas G, Solomos D, Bakirtzis A, Pissi-missis E, Tzonou A, Cokkinos D. The effects of long-term antithrombotics treatment of left ventricular thrombi in patients after an acute myocardial infarction. Am Heart J 1990; 119: 73-8.
56 Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Ill: Reduction in venous thrombosia and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Br Med J 1994; 308: 235-46.
57 Harenberg J. Prophlaxe der Thrombose und Lungenembolie-Wirksamkeit von Aspirin nicht belegt. Dtsch Ärzteblatt. 1994 (im Druck)